WuXi AppTec Plans $120 Million Investment in New Integrated Biologics Solution Center to Expedite Biologics Development from Ideas to Clinic

SHANGHAI, Jan. 8, 2016 /PRNewswire/ -- WuXi AppTec Co. Ltd. (WuXi), a leading open-access R&D capability and technology platform company serving the global pharmaceutical, biotechnology, and medical device industries, announced today that it has started construction of a state-of-the-art integrated biologics solution center at the company's headquarters in Shanghai.  The company plans to invest a total of $120 million in this dedicated, 250,000-square-foot facility, which will be operational in 2017 and accommodate 800 scientists.  The facility will provide integrated solutions from ideas to the clinic for biologics discovery, development, and clinical manufacturing on a consolidated campus. 

The biologics discovery center will utilize the state-of-the-art OmniRat™ platform in collaboration with Open Monoclonal Technology, Inc., and in-house proprietary phage display libraries to enable global clients to discover conventional mAbs, bi-specific mAbs and antibody-drug conjugates.  The biologics development center will utilize WuXi's proprietary CHO cell line platform to develop robust fed-batch and perfusion processes to meet demanding processing needs.  The co-located cGMP clinical manufacturing facilities will support four concurrent campaigns using 3x2000L fed-batch and 2x500L perfusion bioreactors.  With this comprehensive platform integrated from discovery through all aspects of development, customers will benefit from the speed, agility, efficiency, and unsurpassed quality of WuXi's operations to expedite their global biologics research and development.

"We are very pleased to continue to invest in our biologics capabilities and expand our capacities to support the ambitious plans of our global clients," said Dr. Ge Li, Chairman and CEO of WuXi AppTec.  "Through this investment, WuXi will further strengthen its position as a global leader in biologics R&D, offering a truly unique integrated solution."

About WuXi AppTec

WuXi AppTec is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States.  As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology, and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process.  WuXi is also building a platform to provide clinical diagnostic services directly to physicians and their patients globally.  WuXi AppTec's services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D.  For more information on WuXi's biologics services, please visit: http://www.wuxiapptec.com/biologics.html.

Suggested Articles

Hengrui's Sun Piaoyang is stepping down as chairman, but he'll retain control of the pharma major he's headed for 30 years—and made a fortune…

Astellas tapped Adaptimmune to develop T-cell therapies. Ireland hit Takeda with an unexpected Shire tax bill. PD-1 med Tyvyt hit its goal in NSCLC.

South Korea’s Celltrion, which has a massive biologics site in Songdo, has decided it is time to build some operations in China.